Rosemary S. L. Wong

Learn More
PURPOSE/OBJECTIVE(S) American Indians (AIs) present with more advanced stages of cancer and, therefore, suffer from higher cancer mortality rates compared to non-AIs. Under the National Cancer Institute (NCI) Cancer Disparities Research Partnership (CDRP) Program, we have been researching methods of improving cancer treatment and outcomes since 2002, for(More)
PURPOSE To increase access of underserved/health disparities communities to National Cancer Institute (NCI) clinical trials, the Radiation Research Program piloted a unique model - the Cancer Disparities Research Partnership (CDRP) program. CDRP targeted community hospitals with a limited past NCI funding history and provided funding to establish the(More)
and represents an ideal target for growth inhibition and cell killing. Several reviews describe DNA topoisomerases as chemotherapeutic targets (2, 5†" 7). VP-163 is a non-intercalative antitumor agent proposed to inhibit strand-passing activity (2, 5, 3, 8, 9) by stabilizing a cleavable com plex between topoisomerase II and DNA, thus interfering with the(More)
  • 1